News Focus
News Focus
icon url

Maple tree

04/07/17 7:08 PM

#2975 RE: Whatsupp #2964

The company tries to keep stock price floating so can sell shares to retail investors. Look at last 18 months, outstanding shares increased to 41 millions from 31 millions.
icon url

XenaLives

04/07/17 8:44 PM

#2976 RE: Whatsupp #2964

The FDA doesn't "approve" P2s, they "approve" P3.

Anavex CEO has stated that they are in touch with the FDA concerning trial design.

Missling has been extremely conservative in diluting the stock and I don't expect that to change.